¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Journal of clinical laboratory analysis."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Kaplan-Meier analysis
    Ä«Çöõ-¸¶À̾îºÐ¼®
  • linkage analysis
    ¿¬°üºÐ¼®
  • multipoint linkage analysis
    ´ÙÁ¡¿¬°üºÐ¼®
  • multivariate analysis
    ´Ùº¯·®ºÐ¼®, ´Ù¿äÀκм®
  • meta-analysis
    ¸ÞŸºÐ¼®
  • nephelometric analysis
    ȥŹºÐ¼®
  • Northern blot analysis
    ³ë´øºí·ÔºÐ¼®
  • polarimetric analysis
    Æí±¤ºÐ¼®
  • precipitation analysis titration
    ħÀüºÐ¼®ÀûÁ¤
  • process analysis
    °øÁ¤ºÐ¼®, °úÁ¤ºÐ¼®
  • path analysis
    °æ·ÎºÐ¼®
  • qualitative analysis
    Á¤¼ººÐ¼®
  • quantitative analysis
    Á¤·®ºÐ¼®
  • radiochemical analysis
    ¹æ»çÈ­Çкм®
  • radiometric analysis
    ¹æ»ç¼±°èÃøºÐ¼®
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • nephelometric analysis
    ȥŹºÐ¼®
  • path analysis
    °æ·ÎºÐ¼®
  • polarimetric analysis
    Æí±¤ºÐ¼®
  • principal component analysis
    ÁÖ¼ººÐºÐ¼®
  • process analysis
    °øÁ¤ºÐ¼®, °úÁ¤ºÐ¼®
  • qualitative analysis
    Á¤¼ººÐ¼®
  • quantitative analysis
    Á¤·®ºÐ¼®
  • radiochemical analysis
    ¹æ»çÈ­Çкм®
  • radiometric analysis
    ¹æ»ç¼±ºÐ¼®
  • regression analysis
    Èֱͺм®
  • risk benefit analysis
    À§ÇèÆíÀͺм®
  • sequential analysis
    ¼øÂ÷ÀûºÐ¼®
  • situation analysis
    »óȲºÐ¼®
  • Southern blot analysis
    ¼­´øºí·ÔºÐ¼®
  • statistical analysis
    Åë°èºÐ¼®
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • clinical significance
    ÀÓ»óÀû Á߿伺(¡­ñìé©àõ)
  • clinical specimen
    Àӻ󰡰˹°, ÀÓ»ó°Ëü
  • clinical syndrome
    ÀÓ»ó(Àû) ÁõÈıº
  • clinical target volume, CTV
    ÀÓ»óÇ¥ÀûüÀû
  • clinical trial
    ÀÓ»ó½ÃÇè.
  • clinical trial
    ÀÓ»ó½ÃÇè
  • clinical unit
    ÀÓ»ó´ÜÀ§(¡­Ó¤êÈ).
  • clinical use
    ÀÓ»óÀû(ÀÎ) ÀÌ¿ë
  • clinical virology
    ÀÓ»ó¹ÙÀÌ·¯½ºÇÐ
  • clinical ward
    ÀÓ»óº´µ¿(¡­Ü»ÔÖ).
  • clinical-pathological correlation
    ÀÓ»ó-º´¸®ÇÐÀû »óÈ£°ü°è(ìúßÉ-Ü»×âùÊîÜ ßÓû»Î¼Ìõ)
  • controlled clinical study
    (Ãß°èÇÐÀû) °ü¸®È­(Ì§Ë­Ì°ËøË´ËöÌ´)(ÀÓ»ó)½ÃÇè( ËöË×ËàÌ´).
  • mycology, clinical
    ÀÓ»óÁø±ÕÇÐ
  • randomized clinical trial
    ¹«ÀÛÀ§ÀÓ»ó½ÇÇè
  • structured clinical interview
    ±¸Á¶È­µÈ ÀÓ»ó¸éÁ¢(ìúßÉØüïÈ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
ACLA American Clinical Laboratory Association
ACLPS Academy of Clinical Laboratory Physicians and Scientists
ASCLT American Society of Clinical Laboratory Technicians
CCLI composite clinical and laboratory index
CL capillary lumen; cardiolipin; cell line; centralis lateralis; chemiluminescence; chest and left arm ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
CDSS Clinical Decision Support System
CDR Clinical Dementia Rating
CDR Clinical Dementia Rating Scale
CGI Clinical Global Impression
CGI Clinical Global Impression Scale
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • mixed dentition analysis
    È¥ÇÕ Ä¡¿­±âÀÇ ¾Ç±Ã °ø°£ ºÐ¼®
    È¥ÇÕ Ä¡¿­±â ±³ÇÕÀº ¿µ±¸ Á¦1 ´ë±¸Ä¡°¡ ¸ÍÃâÇÏ´Â 6-7¼¼ºÎÅÍ Çü¼ºµÈ´Ù. ½ÃÁø ¹× ±¸°­ ¹æ»ç¼±ÇÐÀû °Ë»çÀÇ È°¿ëÀ» ÅëÇØ ¿µ±¸Ä¡ ¸ÍÃâ ¼ø¼­¸¦ »ìÆìº¸´Â °ÍÀº Á¤»ó ±³ÇÕ Çü¼ºÀÇ °¡´É¼º ÆÇ´Ü¿¡ À¯È¿ÇÑ Á¤º¸¸¦ Á¦°øÇØ ÁØ´Ù.
  • occlusal analysis
    ±³ÇÕ ºÐ¼®
    ±³Çձ⿡ ÀåÂøµÈ ¸ðÇüÀÇ ±³ÇÕ °ü°è¸¦ Æò°¡ÇÏ´Â ±³ÇÕ.
  • qualitative analysis
    Á¤¼º ºÐ¼®
    È­ÇÐ ºÐ¼®¹ý Áß¿¡¼­ ½Ã·á°¡ ¾î¶² ¼ººÐÀ¸·Î ±¸¼ºµÇ¾î ÀÖ´ÂÁö ¾Ë¾Æ³»±â À§ÇÑ ºÐ¼®¹ýÀÇ ÃÑĪ. ÀϹÝÀûÀ¸·Î Á¤·® ºÐ¼®À» Çϱâ Àü¿¡ Á¤¼º ºÐ¼®À» ÇÏ°Ô µÈ´Ù. ¹°ÁúÀ» ±¸¼ºÇϰí ÀÖ´Â È­ÇÐÁ¾
  • script analysis
    °¢º» ºÐ¼®
    »çȸ¿¡ Âü¿©ÇÒ ¶§ Çൿ ¾ç»óÀÇ Æ²ÀÎ °¢º»ÀÌ ¸¸µé¾îÁö´Â °úÁ¤¿¡ ´ëÇÑ ºÐ¼®.
  • sequential analysis
    ¼øÂ÷Àû ºÐ¼®
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • space analysis
    °ø°£ ºÐ¼®
  • spectral analysis
    ½ºÆåÆ®·³ ºÐ¼®
    ¹°ÁúÀÇ ¹æÃâ ½ºÆåÆ®·³ ¶Ç´Â Èí¼ö ½ºÆåÆ®·³À» Á¶»çÇÏ¿©, ±× ¼Ó¿¡ ÀÖ´Â ¼ººÐ ¿ø¼Ò³ª È­ÇÕ¹°ÀÇ Á¾·ù¿Í ¾çÀ» ÆÇÁ¤ÇÏ´Â ¹æ¹ý. ºÐ±¤ È­ÇÐ ºÐ¼®À̶ó°íµµ ÇÑ´Ù. 19¼¼±â Áß¿±¿¡ R. ºÐÁ¨ÀÌ G. ۸£È÷È£ÇÁÀÇ Çù·ÂÀ» ¾ò¾î È®¸³½ÃŲ ½ÇÇè ±â¼úÀ̸ç, º¸ÅëÀÇ È­ÇÐ ºÐ¼®¿¡ ºñÇÏ¿© Á¶ÀÛÀÌ ºü¸£°í, ¼Ò·®ÀÇ ½Ã·á·Îµµ ºÐ¼®ÀÌ °¡´ÉÇÑ ÀÌÁ¡ÀÌ ÀÖ´Ù. ¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ °Í°ú, Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ °ÍÀÇ µÎ °¡Áö·Î Å©°Ô ³ª´­ ¼ö ÀÖ´Ù. ¡¼¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ¼®¡½ ¿øÀÚ¿¡¼­ ¹æÃâµÇ´Â ºûÀÇ ½ºÆåÆ®·³ÀÌ °¢ ¿ø¼Ò¿¡ µû¶ó °íÀ¯ÇÔÀ» ÀÌ¿ëÇÔÀ¸·Î½á, ½Ã·á¸¦ ¹ß±¤½ÃÄÑ ½ºÆåÆ®·³À» °Ë»çÇϰí, ¹Ì¸® Á¶»çÇÏ¿© µÐ Ç¥ÁØ ½Ã·áÀÇ ¹æÃâ ½ºÆåÆ®·³À» ±âÃÊ·Î ¼ººÐ ¿ø¼ÒÀÇ Á¾·ù³ª ¾çÀ» ¾Ë¾Æ³»´Â ¹æ¹ýÀÌ´Ù. °ËÃâÀÇ Á¤¹Ðµµ´Â ¿ø¼Ò¿¡ µû¶ó ´Ù¸£Áö¸¸, ÀϹÝÀûÀ¸·Î È­ÇÐ ºÐ¼®¿¡ ºñÇÏ¿© °¨µµ°¡ ³ô°í, ƯÈ÷ ±Ý¼Ó¿¡ ¹Ì·®À¸·Î ÇÔÀ¯µÇ¾î ÀÖ´Â ºÒ¼ø¹° ¿ø¼ÒÀÇ ¹ß°ßÀ̳ª Á¤·® µî¿¡´Â ÁÁÀº °á°ú¸¦ ¾òÀ» ¼ö ÀÖ´Ù. ½Ã·á¸¦ ¹ß±¤½ÃŰ´Â µ¥´Â º¸Åë ½Ã·á¸¦ ÇÑÂÊ ±ØÀ¸·Î ÇÏ´Â ¾ÆÅ© ¹æÀüÀ̳ª, ±âü »óÅÂÀÇ ½Ã·á¸¦ ¹æÀü°ü¿¡ ä¿ö¼­ ¹æÀü½ÃŰ´Â ¹æ¹ýÀÌ ÀÌ¿ëµÈ´Ù. ¾ËÄ®¸® ±Ý¼ÓÀ̳ª ¾ËÄ®¸®Åä ±Ý¼Ó¿¡ ´ëÇÑ ºÒ²É ¹ÝÀÀÀ» ÀÌ¿ëÇÑ ºÒ²É ½ÃÇèµµ ¹æÃâ ½ºÆåÆ®·³¿¡ ÀÇÇÑ °£´ÜÇÑ ºÐ±¤ ºÐ¼®À̶ó ÇÒ ¼ö ÀÖ´Ù. ¡¼Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ¼®¡½ ±âü³ª ¿ë¾×¿¡ ¿¬¼Ó ½ºÆåÆ®·³À» °¡Áø ºûÀ» Á¶»çÇϸé, ±× ¼Ó¿¡ Á¸ÀçÇϴ Ȭ ¿ø¼ÒÁúÀ̳ª È­ÇÕ¹°ÀÌ °¢°¢ ƯÀ¯ÇÑ ÆÄÀåÀÇ ºûÀ» ¼±ÅÃÀûÀ¸·Î Èí¼öÇϹǷÎ, Åõ°ú±¤ÀÇ ½ºÆåÆ®·³¿¡´Â ¹°ÁúÀÇ Á¾·ù¿¡ µû¶ó ƯÀ¯ÇÑ ¹è¿­À» °¡Áø Èí¼ö ¼±ÀÌ ³ªÅ¸³­´Ù. µû¶ó¼­, ¾î¶² ¾ç ¶Ç´Â µÎ²²ÀÇ ¼ø¼öÇÑ ¹°ÁúÀÇ Èí¼ö ½ºÆåÆ®·³À» ¸¹ÀÌ °®Ãß°í ÀÖÀ¸¸é, À̰ÍÀ» ±âÃÊ·Î ÇÏ¿© ¹ÌÁö ½Ã·áÀÇ Á¤¼º ºÐ¼®, ¾Ë°í ÀÖ´Â ½Ã·áÀÇ Á¤·® ºÐ¼®, ½Ã·á ¼Ó¿¡ ÀÖ´Â ºÒ¼ø¹°ÀÇ ¹ß°ß ¹× Á¤·®ÇÒ ¼ö ÀÖ´Ù. À̰ÍÀÌ Èí¼ö ½ºÆåÆ®·³¿¡ ÀÇÇÑ ºÐ±¤ ºÐ¼®À̸ç, ƯÈ÷ ¿ë¾× ¼Ó¿¡ Á¸ÀçÇÏ´Â ºñŸ¹Î·ùÀÇ Á¤·® µîÀº ÀÌ ¹æ¹ýÀ» »ç¿ëÇÏ¸é ½±°Ô ¾Ë ¼ö ÀÖ´Ù. ºÐ±¤ ºÐ¼®Àº ½ºÆåÆ®·³ ºÐ¼®À̶ó°íµµ Çϴµ¥, ½ºÆåÆ®·³ ºÐ¼®À̶ó°í ÇÒ ¶§´Â ÀÌ»ó°ú °°Àº ºÐ¼® È­Çп¡ÀÇ ÀÀ¿ë ¿Ü¿¡, ¹°ÁúÀÇ ¹æÃâ ¶Ç´Â Èí¼ö ½ºÆåÆ®·³À» Á¤¹ÐÈ÷ ÃøÁ¤, ÇØ¼®ÇÏ¿© ¹°ÁúÀÇ ¿¡³ÊÁö ÁØÀ§, ÀüÀÌ È®·ü, ºÐÀÚÀÇ °áÇÕ °£°ÝÀ̳ª ºÐÀÚ ±¸Á¶ÀÇ °áÁ¤ µî¿¡µµ ÀÌ¿ëµÈ´Ù.
  • spectrophotometric analysis
    ºÐ±¤ ±¤µµ ºÐ¼®
  • statistic :

    statistical analysis

    Åë°èÀû ºÐ¼®
  • stress analysis
    ÀÀ·Â ºÐ¼®
  • synovial fluid analysis
    Ȱ¾× ºÐ¼®
  • thermal analysis
    ¿­ ºÐ¼®
  • urine analysis
    ¿ä °Ë»ç, ¼Òº¯ ºÐ¼®
    µ¿ÀǾî=urinalysis.
  • volumetric analysis
    ¿ë·® ºÐ¼®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
clinical trial <pharmacology> Research study conducted with patients, usually to evaluate a new treatment or drug. Each trial is designed to answer scientific questions and to find better ways to treat individuals with a specific disease.
(12 May 1997)
clinical trial, phase I A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on a small number of healthy persons and conducted over the period of about a year in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase II A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques based on several hundred volunteers, including a limited number of patients, and conducted over a period of about two years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase III A pre-planned, usually controlled, clinical study of the safety and efficacy of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques after phase II trials. A large enough group of patients is studied and closely monitored by physicians for adverse response to long-term exposure, over a period of about three years in either the united states or a foreign country.
(12 Dec 1998)
clinical trial, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale after clinical trials, phases I, II, and III. These studies, conducted in the united states or a foreign country, often garner additional data about the safety and efficacy of a product.
(12 Dec 1998)
clinical trials Medical research studies conducted with volunteers. Each study is designed to answer scientific questions and to find better ways to prevent, detect, or treat cancer.
(12 Dec 1998)
clinical trials, phase I Studies performed to evaluate the safety of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques in healthy subjects and to determine the safe dosage range (if appropriate). These tests also are used to determine pharmacologic and pharmacokinetic properties (toxicity, metabolism, absorption, elimination, and preferred route of administration). They involve a small number of persons and usually last about 1 year. This concept includes phase I studies conducted both in the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase II Studies that are usually controlled to assess the effectiveness and dosage (if appropriate) of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques. These studies are performed on several hundred volunteers, including a limited number of patients with the target disease or disorder, and last about two years. This concept includes phase II studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase III Comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
clinical trials, phase IV Planned post-marketing studies of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques that have been approved for general sale. These studies are often conducted to obtain additional data about the safety and efficacy of a product. This concept includes phase IV studies conducted in both the u.s. And in other countries.
(12 Dec 1998)
controlled clinical trial A clinical trial involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicine, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trial is characterised as a randomised controlled trial. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes are simply designated as controlled clinical trials.
(12 Dec 1998)
controlled clinical trials Clinical trials involving one or more test treatments, at least one control treatment, specified outcome measures for evaluating the studied intervention, and a bias-free method for assigning patients to the test treatment. The treatment may be drugs, devices, or procedures studied for diagnostic, therapeutic, or prophylactic effectiveness. Control measures include placebos, active medicines, no-treatment, dosage forms and regimens, historical comparisons, etc. When randomization using mathematical techniques, such as the use of a random numbers table, is employed to assign patients to test or control treatments, the trials are characterised as randomised controlled trials. However, trials employing treatment allocation methods such as coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are simply designated as controlled clinical trials.
(12 Dec 1998)
cytogenetics, clinical The application of cytogenetics to clinical medicine. For example, clinical cytogenetic studies might be done to determine whether a child with possible Down syndrome has an extra chromosome 21.
(12 Dec 1998)
prospective, randomised, double-blind clinical trial <statistics> A clinical trial in which the method for analysing data has been specified in the protocol before the study has begun (prospective), the patients have been randomly assigned to receive either the study drug or alternative treatment, and in which neither the patient nor the physician conducting the study know which treatment is being given to the patient.
(13 Nov 1997)
psychology, clinical The branch of psychology concerned with psychological methods of recognizing and treating behaviour disorders.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á